Neurogene (NGNE) has released an update.
Neurogene Inc. has reached a significant milestone in its Phase 1/2 clinical trial for Rett syndrome by safely administering a high-dose of its gene therapy, NGN-401, with no new adverse events reported. Interim safety results show the treatment is well-tolerated, and the company anticipates sharing further efficacy data by the end of 2024. These promising developments could lead to a new best-in-class treatment for patients with this rare neurological disorder.
For further insights into NGNE stock, check out TipRanks’ Stock Analysis page.
